01
Double-chamber cartridge
The dry research compound and sterile water are sealed in separate chambers, avoiding a pre-mixed liquid during storage and transport.
Research compound · 20 mg
Retatrutide
20 mg
A focused research presentation from J-Pep Labs, with clear product information and direct access to independent batch documentation.
For laboratory research use only. Not for human consumption or medical use.
J-Pep Labs20 mg
20 mgDeclared vial content
LyophilizedPowder presentation
Batch COAIndependent report access
About the compound
One peptide.
A clear purpose.
Retatrutide, also known by the clinical-development code LY3437943, is an investigational peptide designed as a triple agonist at the GIP, GLP-1 and glucagon receptors.
J-Pep Labs focuses on 20 mg lyophilized research presentations, including the standard vial and a convenient double-chamber cartridge format. This website provides product facts, scientific context, batch-documentation access and a direct contact channel.
A more convenient format
Two chambers.
One simple activation.
J-Pep Labs is helping lead the move toward a double-chamber cartridge presentation: lyophilized Retatrutide remains physically separate from sterile water until the system is activated.
02
Disposable mixing pen
The self-contained pen provides a clean, compact way to activate the cartridge, prepare the solution and dispense it for the intended research workflow.
How it works
Twist. Mix. Prepare.
- Keep separatePowder and sterile water remain isolated until activation.
- Twist to activateTurning the pen advances the internal stopper so the diluent enters the powder chamber.
- Gently mixRoll or swirl as directed until dissolved; do not shake unless the supplied instructions specifically say otherwise.
Storage note: Keeping the compound dry until activation avoids transporting a pre-mixed solution. Refrigeration-free storage should only be stated when supported by validated stability data; always follow the product label before and after mixing.
Why it is being studied
Three pathways.
One research molecule.
Retatrutide remains investigational. The points below summarize scientific interest and published trial findings; they are not claims about the J-Pep Labs vial and are not medical advice.
Triple-receptor design
Retatrutide is a single investigational molecule designed to activate GIP, GLP-1 and glucagon receptors.
Metabolic research interest
The three-pathway mechanism is being studied for its effects on appetite, energy balance and metabolic markers.
Published trial signal
A phase 2 obesity trial reported dose-dependent body-weight reduction over 48 weeks, supporting continued clinical research.
Batch transparency
Check the independent COA.
Open this batch's Janoshik report directly to review its laboratory documentation. Always match the product lot to the report and check identity, measured quantity and chromatographic purity as separate results.
Open this COA on Janoshik ↗Important: A laboratory report applies only to the tested sample and listed test scope. It does not approve a product for human use or establish sterility unless sterility is separately tested and reported.
Contact J-Pep Labs
Questions about the
product or its COA?
Send your enquiry directly from this page. It will arrive at info@j-peplabs.com, and we can reply to the email address you provide.